Related Experiment Video
Updated: May 8, 2026

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
Native aortic valve regurgitation: transcatheter therapeutic options
David Roy1, Rajan Sharma, Stephen J D Brecker
1Department of Cardiology, St George's Healthcare NHS Trust, London, United Kingdom.
Abstract:
Transcatheter aortic valve implantation (TAVI) is an acceptable treatment for patients with aortic stenosis but remains contraindicated for patients with native aortic valve regurgitation (NAVR). It is well established that patients with severe NAVR and symptoms have a poor prognosis if left untreated and that they should be offered surgical aortic valve replacement. There are patients with NAVR and at high surgical risk for whom conventional surgical aortic valve replacement may be unsuitable. Until recently there has been limited experience in the treatment of these patients with TAVI but outcomes from isolated case reports and small registries are encouraging. Of interest are certain new TAVI devices with design features which may make them better suited to the treatment of NAVR patients.
Related Concept Videos
Aortic Regurgitation III: Medical Management
Mitral Regurgitation III: Medical Management
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aortic Regurgitation I: Introduction
Aortic Regurgitation IV: Nursing Management
Mitral Stenosis III: Medical Management